Background/Aims: Lubeluzole is a benzothiazole derivative that has shown neuroprotective properties in preclinical models of ischemic stroke. However, clinical research on lubeluzole is now at a standstill, since lubeluzole seems to be associated with the acquired long QT syndrome and ventricular arrhythmias. Since the cardiac cellular effects of lubeluzole have not been described thus far, an explanation for the lubeluzole-induced QT interval prolongation is lacking. Methods: We tested the affinity of lubeluzole, its enantiomer, and the racemate for hERG channel using the patch-clamp technique. We synthesized and tested two simplified model compounds corresponding to two moieties included in the lubeluzole structure. The obtained experimental results were rationalized by docking simulation on the recently reported cryo-electron microscopy (cryo-EM) structure of hERG. Group efficiency analysis was performed in order to individuate the fragment most contributing to binding. Results: We found that lubeluzole and its R enantiomer are highly potent inhibitors of human ether-ago-go-related gene (hERG) channel with an IC 50 value of 12.9 ± 0.7 nM and 11.3 ± 0.8 nM, respectively. In the presence of lubeluzole, steady-state activation and inactivation of hERG channel were shifted to more negative potentials and inactivation kinetics was accelerated. Mutations of aromatic residues (Y652A and F656A) in the channel inner cavity significantly reduced the inhibitory effect of lubeluzole. Molecular docking simulations performed on the near atomic resolution cryo-electron microscopy structures of hERG supported the role of Y652 and F656 as the main contributors to high affinity binding. Group efficiency analysis indicated that both 1,3-benzothiazol-2-amine and 3-aryloxy-2-propanolamine moieties contribute to drug binding with the former giving higher contribution. Conclusions: This study suggests the possibility to modulate lubeluzole hERG blockade by introducing suitable substituents onto one or both constituting portions of the parent compound in order to either reduce 
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Introduction
Lubeluzole [(S-1), Fig. 1A ] is a benzothiazole derivative that has shown neuroprotective properties in preclinical models of ischemic stroke. The exact mechanism of neuroprotection exerted by lubeluzole, in both clinical and experimental models of cerebral ischemia [1] , is not clearly defined. In fact, the drug seems to modulate in vitro different molecular pathways. It inhibits the signal transduction mechanisms of nitric oxide (NO) [2] , the release of glutamate [3, 4] , and blocks Q-type voltage-gated Ca 2+ channels [5] . In addition, the drug blocks voltagegated sodium channels in brain neurons and cardiomyocytes [6, 7] , but it has been recently reported that its neuroprotective action is not triggered by sodium channel inhibition [8] . Since lubeluzole inhibits neuronal cyclic guanosine monophosphate (cGMP) accumulation, it has been proposed that inhibition of neuronal nitric oxide pathways may represent the main mechanism of neuroprotection [2] . The anti-ischemic activity of lubeluzole has also been related to calmodulin (CaM) activity and the counteraction of osmotic stress (mechanism associated with the release of the active amino acid taurine) [9] . The affinity of lubeluzole for CaM and its inhibiting activity on Ca 2+ /CaM-dependent kinase II at the low micromolar level have recently been reported [10] .
Moreover, lubeluzole has shown reductions of infarct volume and improved neurological function in a photothrombotic occlusion model in rats [11] , and in a conventional permanent Middle Cerebral Artery Occlusion (MCAO) model also in rats [12] , although the neuroprotective effects in the MCAO model were lost if administration was delayed by more than 30 minutes after onset of ischaemia. Recently, it has been demonstrated that lubeluzole synergizes with both doxorubicin and paclitaxel on human ovarian adenocarcinoma and lung carcinoma cells, respectively, over a wide concentration range (0.005-5 µM) [13] ; the lowest concentration was at least 40 times lower than human plasma concentrations clinically relevant for the anti-ischemic activity [14] . In view of the above considerations, lubeluzole has been recently included in a list of sodium channel blocker candidates to repositioning [15] .
Despite these promising in vitro and in vivo results, clinical research on lubeluzole is now at a standstill, since lubeluzole seems to be associated with a significant increase of heart-conduction disorders. In particular, therapeutic lubeluzole concentrations increase the action potential duration, thus causing the prolongation of the QT interval of the electrocardiogram in some of the treated patients [16, 17] . The Cochrane systematic review of lubeluzole trials [18] , involving 3510 patients in five trials, confirmed lack of benefit and also significant excess risk of cardiac conduction abnormalities at all doses, including the 10 mg dose employed in most trials.
The prolongation of QT waves, caused by cardiotoxic drugs, has mainly been related to the inhibition of I Kr , the current carried by the human ether-a-go-go-related gene (hERG) channel [19] . Based on this experimental evidence, as well as the finding that specific mutations in hERG are responsible for one form of congenital long-QT syndrome [20] , the hERG channel assay is now considered an important antitarget in the preclinical safety testing process [21] .
Since the cardiac cellular effects of lubeluzole have not been described thus far, an explanation for the lubeluzole-induced QT interval prolongation is lacking. In this article we i) tested the affinity of lubeluzole, its enantiomer, and the racemate for hERG channel using the patch-clamp technique; ii) investigated the hERG channel residues involved in the binding of lubeluzole; iii) searched for the main molecular determinants of lubeluzole block of hERG. This latter goal was pursued by designing, preparing, and testing two simplified model compounds corresponding to two moieties included in the lubeluzole structure. The obtained experimental results were rationalized by docking simulation on the recently reported cryo-electron microscopy (cryo-EM) structure of hERG [22] . Group efficiency analysis was performed in order to identify the fragment most contributing to binding.
Materials and Methods

Chemistry
Lubeluzole [(S)-1], its R enantiomer [(R)-1], the corresponding racemate, and N-methyl-N-piperidin-4-yl-1, 3-benzothiazol-2-amine (3) (Fig. 1A) were prepared following or adapting previously reported procedures [23, 13] . Compound 3 was then converted into its hydrochloride salt by treatment with a few drops of 2 M HCl and azeotropically removing water. (Fig. 1A ) was obtained following a previously reported procedure [8] .
Maintenance of mammalian cell lines and cell transfection
Patch-clamp studies were carried out on Human Embryonic Kidney (HEK) 293 cells stably transfected with hERG1a isoform, (DI.V.A.L. Toscana srl, Italy) and Chinese Hamster Ovary (CHO) cells transiently expressing hERG mutants. For heterologous protein expression, cells were plated in 6-well cell culture dishes with 2 mL growth medium, 24 h before transfection. Cells were transiently transfected with hERG mutants using TurboFect transfection reagent (Thermo Scientific). EGFP fluorescence was used as markers of successful transfection. Electrophysiology studies were performed 48/72 hr after transfection.
Electrophysiological recordings
Electrophysiological recordings were performed using the whole-cell mode of the patch-clamp technique. The extracellular solution used for patch-clamp recordings had the following composition: 140 mM NaCl, 5 mM KCl, 1 mM MgCl 2 , 2 mM CaCl 2 , 10 mM Glucose, 10 mM HEPES, pH 7.4 with NaOH. A modified 'high K + ' solution (containing 94 mM KCl and 50 mM NaCl) was used to study T623A and F656A hERG channel mutants [24] [25] [26] . The pipette contained: 145 mM KCl, 10 mM EGTA, 1 mM MgCl 2 , 2 mM Mg-ATP, 10 mM HEPES, pH 7.30 with KOH. Solutions were applied to the cell via a gravity-fed perfusion system (VC-6 Six Channel Valve Controller, Warner Instruments). Patch-clamp electrodes were pulled from Sutter capillary glass (Novato, CA) on a Flaming/Brown type puller (Sutter P-87), and fire polished to 3-4 MΩ resistance, using a microforge (Narishige). To minimize voltage errors, 50-70% of the series resistance was electronically compensated. Patch-clamp recordings of cell cultures were carried out at room temperature 48h after transfection. For recordings a Multiclamp 200B amplifier (Molecular Devices, Inc, Sunnyvale, CA) and Digidata 1440 data acquisition board (Molecular Devices, Inc, Sunnydale, CA) with pCLAMP 10 software (Molecular Devices, Inc, Sunnyvale, CA) were used. Data analysis was performed using Origin 8.0 (OriginLab Corporation, Northampton, MA).
Molecular modeling
Lubeluzole was docked into the near atomic resolution cryo-EM structures of the hERG wild type (WT) (pdb: 5VA1, 3.7 Å resolution) and S631A mutant channels (pdb: 5VA3, 4.0 Å resolution) using the program Gold4.0.1 (Cambridge DataCentre, Cambridge, UK, [27] ). Protein flexibility was realized including 20 snapshots derived from unbiased 500 ns all-atom Molecular Dynamics simulations (for all online suppl. material, see www.karger.com/doi/10.1159/000488169, Suppl. methods). The binding site radius was set to 20 Å around the geometric centers of Y652, which lead to a selection including all experimentally observed hERG binding determinants [20, 28, 29] , as well as the hydrophobic pouches behind the selectivity filter [22] . 100, 000 operations of the GOLD genetic algorithm were used to dock both enantiomers. 100 docking poses per run were stored, with the 20 highest ranked poses analyzed in detail.
Results
Effect of lubeluzole on WT hERG
To investigate the effect of lubeluzole [(S)-1], its R enantiomer [(R)-1], and the racemic mixture (Fig. 1A) on hERG potassium channels, patch-clamp experiments were performed on HEK cells heterologously expressing the hERG channel. To elicit the activating outward
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Cellular Physiology and Biochemistry current, a depolarizing step from a holding potential of -80 mV to 0 mV (3 s in duration) was applied. Tail current was evoked by repolarizing to -40 mV for 3 s. Successive command pulses were applied at 10-second intervals. Fig. 1B shows representative recordings of WT I hERG in the absence (control) and in the presence of lubeluzole (100 nM). In the presence of lubeluzole, the tail current was strongly reduced and the I hERG block induced by lubeluzole was almost irreversible, even after 10 min. of perfusion with the control solution (Fig. 1C) . The inhibition caused by lubeluzole, its R enantiomer, and the racemic mixture, at each concentration, was calculated using Eq.
(1) (see online suppl. material) and the mean values, after normalization, were plotted as shown in Fig. 1D . Fitting the data in Fig. 1D with the Hill equation [Eq. (2), (see online suppl. material)] yielded an IC 50 of 12.9 ± 0.7 nM and a Hill slope (nH) of 0.84 ± 0.05, for lubeluzole; an IC 50 of 11.3 ± 0.8 nM and a nH of 0.79 ± 0.04 for its R enantiomer; an IC 50 of 11.1 ± 0.4 nM and a nH of 1.1 ± 0.03 for the racemic mixture (Fig. 1D ). Since no statistically significant differences between IC 50 values were obtained, we conclude that lubeluzole binds hERG channel in a non-stereoselective manner.
Due to the known low expression and altered kinetic properties of some hERG mutants (in particular T623A and F656A clones), we measured the inward current of the T623A and F656A mutants in high (94 mM) external K + solution, since the external K + concentration increase is aimed to maximize the inward tail currents [25, 26, 30] . Consequently, we tested lubeluzole block of wild-type I hERG under similar experimental conditions, to examine whether a change in the ionic conditions affects hERG affinity toward lubeluzole. Since these values are similar to those found from the concentration-response relationship of hERG outward current inhibition by lubeluzole, we conclude that lubeluzoleinduced block of I hERG is not influenced by the concentration or the direction of flux of K + ions, as in the case of other hERG channel blockers (e.g. flecainide [31] ).
Effect of lubeluzole moieties on WT hERG channels
Structurally, lubeluzole contains two portions: an aryloxypropranolamine moiety, recalling β-adrenergic blockers like propranolol [compound (S)-2, Fig. 1A ] and a 1, 3-benzothiazol-2-amine moiety related to riluzole (compound 3, Fig. 1A ). Both riluzole 
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Cellular Physiology and Biochemistry and propranolol are potent sodium channel blockers. Block of sodium channels caused by riluzole seems to be involved in the efficacy of the drug in amyotrophic lateral sclerosis [32] . Propranolol blocks sodium channels in a similar manner to local anesthetics [33] . In view of their pharmacological properties, we decided to analyze in detail the effects of the two lubeluzole moieties on hERG channels expressed in HEK cells. The aryloxypropranolamine (PPA-lub) and 1,3-benzothiazol-2-amine (BTZ-lub) moieties were analyzed individually or mixed together and their effects on hERG currents are reported in Fig. 1F . Our data show that the IC 50 value of lubeluzole is one order of magnitude lower than those of the two moieties, i.e. IC 50 = 160 ± 12 nM and nH = 1.17 ± 0.22 (BTZ-lub), IC 50 = 109 ± 16 nM and nH = 1.22 ± 0.19 (PPA-lub), and IC 50 = 152 ± 11 nM and nH = 1.40 ± 0.28 (BTZ-lub + PPA-lub). This suggests that lubeluzole binds more effectively to hERG channel with respect to the two moieties, acting individually or mixed in the same solution.
Effect of lubeluzole on hERG activation and deactivation
The voltage-dependence of lubeluzole-induced inhibition was measured on hERG K + current amplitudes, applying the protocol shown in Fig. 2A . Tail currents were elicited by repolarization to -60 mV. Individual tail current amplitudes recorded before (control) or after addition of 10 nM lubeluzole, were normalized to the maximal control amplitude and fitted with a Boltzmann function (Fig. 2B) . The presence of lubeluzole caused a leftshift by -10 mV of the I-V relationship of hERG activation current (Fig. 2C) . Moreover, the voltage required for half-maximal activation (V 1/2 ) was leftwards shifted in the presence of lubeluzole, from -16 ± 3 mV (control) to -24 ± 1 mV (lubeluzole) (Fig. 2D) . Since the V 1/2 value of hERG channels is shifted to more negative potentials in the presence of lubeluzole, we conclude that the drug might affect the activation gating of the channel.
Deactivation time constants were obtained by fitting with a single exponential function the currents recorded using the protocol shown in Fig. 2B . As shown in Fig. 2E , lubeluzole slightly increases the deactivation time constant. Relationship between lubeluzole block and hERG channel inactivation I hERG inhibition by drugs can be influenced (or not) by channel inactivation [34] [35] [36] [37] 25] . Steady-state inactivation currents were measured following the three-step protocol reported in Fig. 3A : channels were inactivated at +60 mV, before short test pulses from -100 mV to +20 mV were applied, to recover the channels from inactivation. Depolarization to +60 mV after these test pulses evoked a large outward inactivating current. Fig. 3A shows sample traces of inactivating current I hERG in the absence (control) and in the presence of 10 nM lubeluzole. Current amplitudes measured after depolarization to +60 mV were normalized, plotted against the corresponding test voltage and fitted by a Boltzmann function (Eq. (3), see online suppl. material). Our data indicate that lubeluzole causes a leftward shift in V 1/2 values of steady-state inactivation, from -55 ± 1 mV in the absence of the drug (control) to -70 ± 1 mV in the presence of lubeluzole (Fig. 3B) .
The effect of lubeluzole on the inactivation time course was also investigated using the protocol shown in Fig. 3C . From a holding potential of -80 mV, a 200 ms test pulse to +60 mV was applied to inactivate the channel. Moreover, a short pulse to -100 mV and voltage steps from -20 mV to +60 mV (300 ms, 10 mV-increments) were applied to elicit a large outward inactivating current. Fig. 3C shows sample traces of inactivating current I hERG in the absence or presence of 10 nM lubeluzole. Inactivation currents were fitted by a single exponential function to extrapolate time constant values. Fig. 3D shows that the inactivation kinetics of hERG channel is significantly accelerated in the presence of lubeluzole.
Effect of mutations in the hERG pore helix and inner cavity on lubeluzole potency
A cluster of three residues (T623, S624 and V625) located in the lower portion of the pore helix-selectivity filter region has been reported to be involved in the binding of different drugs to hERG [20, 28] . Moreover, it was shown that hERG channel blockers are able to bind within the channel inner cavity, interacting with one or two aromatic residues of the S6 domain (Tyr652 and Phe656) [38] . In order to determine the roles of these residues A) Representative hERG current traces, in the absence (control) or presence of 10 nM lubeluzole, elicited by the voltage protocol shown in the middle panel, testing steadystate inactivation currents. B) Normalized steady-state I-V inactivation curves before (control) and after application of 10 nM lubeluzole. Data are expressed as mean ± SEM; error bars for some points are masked by symbols. Solid lines represent fits with Boltzmann function. V 1/2 shifted from -55 ± 1 mV (control), to -70 ± 1 mV (P<0.001, paired t-test; n = 6 cells). Currents traces before and after application of lubeluzole are depicted on an expanded time scale (marked as dotted squares in the pulse protocol). C) Pulse protocol and representative onset of inactivation currents, in the absence (control) or presence of 10 nM lubeluzole. D) Inactivation time constants were derived from currents acquired using the protocol shown in (C), fitted with a single exponential function to the decay of tail currents during the third 300-ms voltage step, and plotted against the membrane potential. Data are expressed as mean ± SEM (n ≥ 5 per data point). ***P<0.001 (Two way ANOVA followed by Bonferroni test). ] solution. The current associated with these mutants was elicited by the standard voltage protocol shown in Fig. 1B (Fig. 4A) . The T623A and F656A mutants were tested under 'high' [K + ] solution and the current was elicited by a hyperpolarizing step to -120 mV in order to obtain an appreciable inward current transient. Representative traces of T623A and F656A currents in the absence (control) and in the presence of 10 nM lubeluzole are shown in Fig. 4B . Different lubeluzole concentrations were tested and a full concentration-response relationship was constructed for each mutant, as shown in Fig. 4C and 4D. The corresponding IC 50 values are summarized in Fig. 4E and Table 1, indicating that the two aromatic residues F656 and Y652 have a prominent role in lubeluzole block of I hERG .
Binding modes of lubeluzole to different hERG channel states
Lubeluzole interactions with the hERG channel in a putative open inactivated (WT cryo-EM structure) and an open activated state (S631A mutant structure) were analyzed performing docking calculations. A close-up view of the predicted drug-binding interactions is shown in Fig. 5 (WT) and Fig. 6 (S631A) . In agreement with mutagenesis data (Fig. 4) , π-π interactions between the benzothiazole ring and the aromatic moiety of the Y652 side chains were observed in the large majority (> 95%) of all docking poses obtained for both WT and S631A channels. Hydrophobic and π-π interactions were frequently observed between the difluorophenoxy ring of lubeluzole and the Y652 and F656 side chains. The protonatable nitrogen is located at the center of the strong electronegative cavity, but no cation-π interactions were observed in any of the docking poses. Hydrogen bonds to residues at the base of the selectivity filter (T623, S624) are not observed, in agreement with the very moderate effects of the respective alanine mutants (Fig. 4E) . No differences between the two enantiomers were seen (data not shown). Generally, the high affinity of the compound in the relative narrow hERG cavities is achieved, via maximizing favorable π-π and hydrophobic contacts with Y652 and F656 and lubeluzole. 
Discussion
Lubeluzole is a benzothiazole derivative that has shown neuroprotective properties in preclinical models of ischemic stroke. However, clinical research on lubeluzole is now at a standstill, since lubeluzole seems to be associated with the acquired long QT syndrome and ventricular arrhythmias.
Our data showed that lubeluzole and its R enantiomer are highly potent inhibitors of hERG current with an IC 50 value of 12.9 ± 0.7 nM and 11.3 ± 0.8 nM, respectively. In the presence of lubeluzole steady-state activation and inactivation of hERG channel were shifted to more negative potentials and inactivation kinetics was accelerated. Mutations of aromatic residues (Y652A and F656A) in the channel inner cavity significantly reduced the inhibitory effect of lubeluzole.
Examination of the binding modes obtained from docking calculations suggests that lubeluzole binds to the central cavity of the hERG channel and π-π and hydrophobic interactions with Y652 and F656 are the main contributors to high affinity binding of this drug.
The recently solved hERG cryo-EM structures at near atomic resolution revealed the existence of hydrophobic pouches protruding from the cavity towards the extracellular side, and a possible role for drug-binding was suggested [22] . However, at least for lubeluzole these regions do not seem to contribute to drug-binding. Only in < 5% of the docking poses the difluorphenoxy moiety of lubeluzole partially protruded into one such hydrophobic pocket. No clear state-dependent changes could be observed, when comparing the WT and S631A docking poses, which might be due to the subtle structural differences and the general low resolution of the structures (3.7 Å and 4 Å).
The presence of low stereoselectivity in hERG blockers is a generally observed feature [40] and may be explained invoking both the plasticity and symmetry of the channel [41] . However, eudismic analysis on bupivacaine enantiomers recently unravelled moderate stereoselectivity (stereoselectivity index, SSI = IC 50 distomer/IC 50 eutomer ~ 7) [42] . While blocking hERG with 1000-fold higher potency than bupivacaine, lubeluzole and its enantiomer displayed no stereoselectivity at all (SSI = 0) thus conflicting with the Pfeiffer's rule [43] . However, the following considerations may help explain the complete lack of stereoselectivity observed in our work (for the sake of simplicity, the discussion will be focused on lubeluzole while all considerations obviously hold for its enantiomer too).
First of all, lubeluzole is at least ten times less basic than bupivacaine, with pK a values being 7.14 [8] and 8.17 [44] for lubeluzole and bupivacaine, respectively. Moreover, the protonatable nitrogen of lubeluzole is displaced by one carbon atom from the stereogenic center, unlike bupivacaine, in which the protonatable nitrogen is closer to the stereogenic Table 1 . Parameters (IC 50 , n H ) derived from the Hill fit of the concentration-response relationships of inhibition of hERG channels (WT, T623A, S624A, V625A, Y652A, F656A) by lubeluzole and its moieties. For all channel variants, the direction of I hERG and the external K + concentration were specified in brackets On the other hand, our modeling experiments showed no cation-π interactions in any docking pose. Secondly, lubeluzole is a relatively flexible compound and its protonatable nitrogen is symmetrically substituted. Thus, even occurring, protonation would not add chiral stereoelectronic demand.
Finally, lubeluzole has a relatively symmetric structure roughly depictable as being constituted by two planar portions spaced by an aliphatic linker. The latter, in turn, bears two possibly less relevant pharmacophoric elements, the hydroxyl group and the partially protonated nitrogen atom. Chirality is conferred by the carbinolic group which bears two methylene groups separating the bulkiest molecular moieties. Thus, it may be assumed that the stereogenic requirements imposed by the chirality center are mitigated by the [45] . It comes as no surprise that lubeluzole (MW = 434 Da, cLog P = 4.7) was at least 10 thousand times more potent than its constituting fragments PPA-lub (MW = 271 Da, cLog P = 3.2) and BTZ-lub (MW = 247 Da, cLog P = 2.4) (Fig. 7) . Less predictable was the light rise in ligand efficiency (LE = 1.37pIC 50 / HA [46] ) observed when passing from the two fragments PPA-lub (LE = 0.21) and BTZ-lub (LE = 0.22) to lubeluzole (LE = 0.26) while generally the contrary is found throughout drug-like molecule space: a decrease in LE is commonly observed with increasing MW [46] . Roughly speaking, this means that the non-hydrogen atoms (HA) constituting the two fragments contribute more efficiently to the binding when the two moieties are linked together to give lubeluzole structure than when acting individually. In fact, lubeluzole presented the highest lipophilic ligand efficiency (LLE = pIC 50 -cLog P) [47] value (3.2, Fig.  7) , thus indicating that it is the most specific ligand out of the three. In other words, the increase in potency observed when passing from the two fragments to lubeluzole was not merely due to increased lipophilicity. However, both LE and LLE values were relatively low, thus indicating that the driving force of lubeluzole blocking activity is mostly entropic (i. e, sustained by van der Waals and hydrophobic contributions [48] ). The last statement is in agreement with the observed null stereoselectivity and docking results.
When group efficiency (GE = ∆∆G/∆number of non-hydrogen atoms = ∆1.37pIC 50 /∆HA) [49, 50] is considered, the 2-aminobenzothiazolic moiety emerged as the most interesting portion (GE = 0.35) since its contribution to lubeluzole potency of block is higher than the one granted by the 3-aryloxy-2-hydroxypropyl portion (GE = 0.32).
Conclusion
Both moieties of lubeluzole contribute to binding. Suitable substituents may be introduced onto both moieties to allow modulation of hERG blocking activity. The benzothiazole ring should be given priority in structure-activity relationship studies.
The interaction of drugs with hERG is generally feared as a source of toxicological concern due to torsadogenic (i. e. proarrhythmic) potential. In this respect, we propose that the introduction of suitable substituents on one or both constituting portions of lubeluzole structure might be exploited to reduce hERG affinity. On the other hand, a therapeutic potential has been suggested for hERG blockers as class III antiarrhythmic and anticancer agents [51] . In this respect, our study let envisage the possibility to develop new lubeluzole analogues possibly endowed with more convenient pharmacological profile through both classical structure-activity relationships and computer-assisted studies.
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